Are Cannabinoids Effective for Orofacial Pain States?

1. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside. Neurotherapeutics 2009;6:713–737.

2. Fine PG, Rosenfeld MJ. Cannabinoids for neuropathic pain. Curr Pain Headache Rep 2014;18:451.

3. McDonough P, McKenna JP, McCreary C, Downer EJ. Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue. Int J Biochem Cell Biol 2014;21;55C:72–78.

4. Liang YC, Huang CC, Hsu KS. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. Neuropharmacol 2007;53:169–177.

5. Papanastassiou AM, Fields HL, Meng ID. Local application of the cannabinoid receptor agonist, WIN 55,212-2, to spinal trigeminal nucleus caudalis differentially affects nociceptive and non-nociceptive neurons. Pain 2004;107:267–275.

6. Burgos E, Pascual D, Martín MI, Goicoechea C. Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests. Eur J Pain 2010;14:40–48.

7. Akerman S, Holland PR, Lasalandra MP, Goadsby PJ. Endocannabinoids in the brainstem modulate dural trigemino-vascular nociceptive traffic via CB1 and “triptan” receptors: Implications in migraine. J Neurosci 2013;33:14869–14877.